Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271331 | 0.82 | GPR119 (0.53) | GPR119S1PR4TGFBR1 | |
| SCHEMBL12320349 | 0.80 | GPR119 (0.47) | GPR119S1PR4TGFBR1MEN1KMT2A | |
| SCHEMBL10116314 | 0.79 | GPR119 (0.47) | GPR119 | |
| SCHEMBL12319885 | 0.78 | GPR119 (0.46) | GPR119S1PR4TGFBR1MEN1KMT2A | |
| SCHEMBL23341813 | 0.71 | PDPK1 (0.36) | MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL10116293 | 0.69 | TRPA1 (0.39) | GPR119MRGPRX1 | |
| SCHEMBL10116291 | 0.69 | LMNA (0.37) | MEN1KMT2A | |
| SCHEMBL10116310 | 0.69 | GPR119 (0.34) | GPR119 | |
| SCHEMBL10116299 | 0.68 | PTGS2 (0.44) | GPR119 | |
| SCHEMBL10116292 | 0.68 | GPR119 (0.55) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | GPR119 1/4885S1PR4 266/4885TGFBR1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.